Neurotrophic Keratitis – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030


 Neurotrophic keratitis is a degenerative corneal disease caused by trigeminal nerve (cranial nerve V) damage, resulting in corneal sensation loss and breakdown of the corneal epithelium. Corneal healing is also hampered in NK, so superficial corneal damage may progress to an actual epithelial defect, followed by corneal ulceration, stromal melting, and perforation. NK treatment aims to restore corneal integrity and prevent the disease from progressing. The cornea, lacrimal glands, conjunctiva, and eyelids are innervated by sensory branches of the ophthalmic division of the trigeminal nerve. The corneal epithelial cells mutually support the corneal nerves by releasing neurotrophic factors that promote neuronal extension and survival. The corneal nerves initiate two protective reflexes, blinking and tear secretion, responding to adverse stimuli. The nerves also support ocular surface health by releasing a host of trophic neuromediators, including substance P and calcitonin gene-related peptides that have been shown to promote corneal epithelial cell proliferation, differentiation, migration, and adhesion.

 

The prevalence of Neurotrophic keratitis ranges from 56 to 67 cases per 100,000 population in the USA.

 

The competitive landscape of Neurotrophic Keratitis includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Neurotrophic Keratitis across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neurotrophic Keratitis Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Neurotrophic Keratitis – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Udonitrectag     Syneos Health   Phase 2

2          rhNGF  Dompé Farmaceutici S.p.A        Phase 2

3          OC-01  Oyster Point Pharma, Inc.          Phase 2

4          CSB-001           Claris Biotherapeutics, Inc.        Phase 2

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033